Chicken egg yolk antibodies (IgY) as non-antibiotic production enhancers for use in swine production: a review

Table 5 Effect of encapsulated IgY on performance and the incidence of diarrhea in pigs challenged with K88+ ETEC¹

Items	No. of pigs	Percentage of pigs with diarrhea after specific times (Fecal score in brackets²)				Weight gain, g³	Recovery rate, (%)
Items	No. of pigs	9 h	24 h	48 h	72 h	Weight gain, g³	Recovery rate, (%)
Negative control, unchallenged	4	0 % (0.5)	0 % (0)	0 % (0.4)	0 % (0)	+1400 ± 129^a	——
Positive control	4	75 % (2.5)	75 % (2.5)	75 % (2.0)	75 % (2.0)	−162.5 ± 25^d	0 %
Non-encapsulated IgY	4	100 % (2.0)	75 % (1.3)	25 % (1.0)	0 % (0)	+937.5 ± 111^b	100 %
Microencapsulated IgY	4	75 % (2.0)	0 % (0)	0 % (0)	0 % (0)	+1325 ± 119^a	100 %
Aureomycin	4	100 % (2.0)	50 % (2.0)	75 % (1.5)	50 % (1.5)	+650 ± 71^c	50 %

Li et al. [83]
¹All pigs except negative control were orally challenged with 5 mL of viable E. coli K88 organisms (10¹¹ cfu/mL per pig) at time 0 h. Challenged pigs were left untreated (positive control) or treated three times (−1, 4 and 9 h after bacterial challenge) on the first day and twice a day for two consecutive days each time with 0.4 g non-encapsulated IgY, 2 g of microencapsulated IgY (equivalent to 0.4 g of IgY) or 0.25 g of aureomycin. Diarrhea and weight gain were assessed for 3 days after challenge
²FC score is the mean fecal consistency score: 0, normal; 1, soft feces; 2, mild diarrhea; 3, severe diarrhea. Pigs with a fecal score of < 1 were considered not to have diarrhea
³Means in a column followed by same or no letter do not differ (P > 0.05)

ISSN: 2049-1891